Kraematon Investment Advisors Inc. Reduces Position in Eli Lilly and Company $LLY

Kraematon Investment Advisors Inc. trimmed its position in Eli Lilly and Company (NYSE:LLY) by 13.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 913 shares of the company’s stock after selling 141 shares during the period. Kraematon Investment Advisors Inc.’s holdings in Eli Lilly and Company were worth $711,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hill Island Financial LLC acquired a new position in shares of Eli Lilly and Company in the second quarter valued at about $341,000. Ergawealth Advisors Inc. raised its position in Eli Lilly and Company by 4.0% during the 2nd quarter. Ergawealth Advisors Inc. now owns 626 shares of the company’s stock worth $488,000 after buying an additional 24 shares during the last quarter. Berger Financial Group Inc lifted its stake in Eli Lilly and Company by 2.6% during the 2nd quarter. Berger Financial Group Inc now owns 6,712 shares of the company’s stock valued at $5,233,000 after acquiring an additional 169 shares during the period. Bay Harbor Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 35.9% in the 2nd quarter. Bay Harbor Wealth Management LLC now owns 178 shares of the company’s stock valued at $139,000 after acquiring an additional 47 shares during the last quarter. Finally, Boston Common Asset Management LLC increased its stake in shares of Eli Lilly and Company by 31.0% in the second quarter. Boston Common Asset Management LLC now owns 35,763 shares of the company’s stock worth $27,878,000 after acquiring an additional 8,468 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on LLY shares. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. Leerink Partners restated a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Cantor Fitzgerald lowered their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Finally, Guggenheim cut their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $938.94.

Eli Lilly and Company Stock Performance

LLY opened at $840.46 on Friday. The company has a market cap of $795.47 billion, a price-to-earnings ratio of 54.93, a PEG ratio of 1.17 and a beta of 0.47. The firm’s fifty day simple moving average is $734.60 and its two-hundred day simple moving average is $765.98. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $3.92 EPS. Eli Lilly and Company’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gabrielle Sulzberger bought 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.